<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938649</url>
  </required_header>
  <id_info>
    <org_study_id>PST008</org_study_id>
    <nct_id>NCT03938649</nct_id>
  </id_info>
  <brief_title>SRAM study_Postate Cancer</brief_title>
  <official_title>Randomized Phase II Study of Combination Androgen Deprivation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer: Stereotactic Body Radiotherapy vs conventionAl IMRT to Prostate and Pelvic Nodes (SRAM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCTU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease
      and/or PSA &gt; 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis.

      Patient will be randomized to:Arm 1

        -  Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to
           proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common
           iliac nodes).

        -  38 fractions of daily treatment, Monday to Friday

      or Arm 2

      SBRT

        -  RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of
           seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)

        -  5 fractions of weekly treatment. Once fraction per week. All patients will be given
           neoadjuvant and adjuvant androgen deprivation therapy (detail as below)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare acute toxicities between SBRT and conventional IMRT</measure>
    <time_frame>4 years</time_frame>
    <description>Toxicities will be assessed by AE CTC version 4 between 2 treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare health-related quality of life (HRQOL) between SBRT and conventional IMRT</measure>
    <time_frame>4 years</time_frame>
    <description>Questionnaire EPIC will be used at pre-treatment, during treatment and at 3, 6, 9, 12, 18 and 24 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the biochemical-failure free survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the progression-free survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the overall survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the late toxicities between 2 treatment arms</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicities will be assessed by AE CTC version 4 between 2 treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).
38 fractions of daily treatment, Monday to Friday</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)
5 fractions of weekly treatment. Once fraction per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional IMRT</intervention_name>
    <description>RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).
38 fractions of daily treatment, Monday to Friday.
All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.</description>
    <arm_group_label>Conventional IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of prostate adenocarcinoma

          -  High risk prostate cancer patients (i.e. T3 to T4 disease and/or PSA &gt; 20 and/or
             Gleason score ≥ 8)

          -  ECOG performance score 0-1

          -  Age ≥ 18

          -  History/physical examination within 2 weeks prior to registration

          -  Able to sign informed-consent

        Exclusion Criteria:

          -  Patients with active cancer other than prostate cancer and non-melanoma skin cancer.

          -  Evidence of distant metastases

          -  Regional lymph node involvement

          -  Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer

          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

          -  Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRH
             antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide),
             estrogens (e.g. DES), or surgical castration (orchiectomy)

          -  Unstable angina and/or congestive heart failure requiring hospitalization, transmural
             myocardial infarction within the last 6 months, acute bacterial or fungal infection
             requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation
             or other respiratory illness requiring hospitalization or precluding study therapy at
             the time of registration

          -  Patients who have received prior chemotherapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darren MC POON, FHKCR</last_name>
    <phone>3505 2128</phone>
    <email>mc_poon@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane KOH, RN</last_name>
    <phone>3505 1142</phone>
    <email>jane@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren MC POON, FHKCR</last_name>
      <phone>35052128</phone>
      <email>mc_poon@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Koh, RN</last_name>
      <phone>35051142</phone>
      <email>jane@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

